332 related articles for article (PubMed ID: 15386651)
1. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
Danzon PM; Wang YR; Wang L
Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
[TBL] [Abstract][Full Text] [Related]
2. Effects of regulation on drug launch and pricing in interdependent markets.
Danzon PM; Epstein AJ
Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
[TBL] [Abstract][Full Text] [Related]
3. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
4. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
5. A game theoretic model of drug launch in India.
Bhaduri S; Ray AS
Health Econ Policy Law; 2006 Jan; 1(Pt 1):23-39. PubMed ID: 18634701
[TBL] [Abstract][Full Text] [Related]
6. External referencing and pharmaceutical price negotiation.
Garcia Mariñoso B; Jelovac I; Olivella P
Health Econ; 2011 Jun; 20(6):737-56. PubMed ID: 20577969
[TBL] [Abstract][Full Text] [Related]
7. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the success rates of new drug development in Japan and the lag behind the US.
Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
[TBL] [Abstract][Full Text] [Related]
9. The quantity and quality of worldwide new drug introductions, 1982-2003.
Grabowski HG; Wang YR
Health Aff (Millwood); 2006; 25(2):452-60. PubMed ID: 16522586
[TBL] [Abstract][Full Text] [Related]
10. Estimating the market for tuberculosis drugs in industrialized and developing nations.
Schwalbe NR; Wells WA; Geaneotes AP; Forcellina A; Lee MG; Dicola L; Ignatius HR; Walker CL; Raafat T; Patel N
Int J Tuberc Lung Dis; 2008 Oct; 12(10):1173-81. PubMed ID: 18812048
[TBL] [Abstract][Full Text] [Related]
11. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
12. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
14. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
Augurzky B; Göhlmann S; Gress S; Wasem J
Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
16. Price regulation and relative delays in generic drug adoption.
Costa-Font J; McGuire A; Varol N
J Health Econ; 2014 Dec; 38():1-9. PubMed ID: 25200940
[TBL] [Abstract][Full Text] [Related]
17. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
18. Risks, prices, and positions: A social network analysis of illegal drug trafficking in the world-economy.
Boivin R
Int J Drug Policy; 2014 Mar; 25(2):235-43. PubMed ID: 24418633
[TBL] [Abstract][Full Text] [Related]
19. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
[TBL] [Abstract][Full Text] [Related]
20. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.
Zhang W; Sun H; Guh DP; Grootendorst P; Hollis A; Anis AH
CMAJ; 2024 May; 196(20):E691-E701. PubMed ID: 38802136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]